<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosbiol</journal-id>
<journal-title-group>
<journal-title>PLOS Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1544-9173</issn>
<issn pub-type="epub">1545-7885</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pbio.1002164</article-id>
<article-id pub-id-type="publisher-id">PBIOLOGY-D-15-00204</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Community Page</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Lee</surname>
<given-names>Wen Hwa</given-names>
</name>
<xref rid="cor001" ref-type="corresp">*</xref>
<xref rid="aff001" ref-type="aff"/>
</contrib>
</contrib-group>
<aff id="aff001"><addr-line>Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The author has declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">wenhwa.lee@sgc.ox.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>4</day>
<month>6</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2015</year>
</pub-date>
<volume>13</volume>
<issue>6</issue>
<elocation-id>e1002164</elocation-id>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Wen Hwa Lee</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pbio.1002164" xlink:type="simple"/>
<abstract>
<p>There is a scarcity of novel treatments to address many unmet medical needs. Industry and academia are finally coming to terms with the fact that the prevalent models and incentives for innovation in early stage drug discovery are failing to promote progress quickly enough. Here we will examine how an open model of precompetitive public–private research partnership is enabling efficient derisking and acceleration in the early stages of drug discovery, whilst also widening the range of communities participating in the process, such as patient and disease foundations.</p>
</abstract>
<abstract abstract-type="toc">
<p>An open access model of precompetitive public–private research partnership can reduce the risks and increase the speed of the early stages of drug discovery, while widening participation to new communities such as patient and disease foundations.</p>
</abstract>
<funding-group>
<funding-statement>The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, CHDI Foundation, Genome Canada, GlaxoSmithKline, the Innovative Medicines Initiative, Janssen, Lilly Canada, Merck &amp; Co., the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<page-count count="9"/>
</counts>
</article-meta>
</front>
<body>
<sec id="sec001">
<title>Open Innovation: Fifty Shades of Grey?</title>
<p>The rate at which new drugs are being discovered has flatlined despite massive investment in research and development (R &amp; D) and new technologies, and there is a common belief that the pharmaceutical business model might be flawed [<xref rid="pbio.1002164.ref001" ref-type="bibr">1</xref>,<xref rid="pbio.1002164.ref002" ref-type="bibr">2</xref>]. Despite a recent upward trend, the number of “first-in-class” therapies has not changed significantly. The fundamental problem is that our understanding of human biology and pathophysiology is too poor to be able to predict the right drug targets for the right patient populations. Therefore, the widespread aversion of institutions and public and private funders to share information prior to and after publication and the overprotection of intellectual property in order to provide return on investment are amongst the most counterproductive practices to the discovery of new medicines. This strategy is at odds with the evidence for enhancing commercial outcomes as well. Most universities lose money through their technology transfer activities [<xref rid="pbio.1002164.ref003" ref-type="bibr">3</xref>] with some notable few exceptions. Most start-up companies do not have a patent at the outset, and it is common that current patenting activities are used to restrict and limit possible uses of underdeveloped discoveries [<xref rid="pbio.1002164.ref004" ref-type="bibr">4</xref>]—a true Tragedy of the Anticommons.</p>
<p>In the last decades, the pharmaceutical industry has accessed many innovative ideas and products through mergers, takeovers, and in-licensing. This trend follows the concepts of Open Innovation, as defined by Chesbrough [<xref rid="pbio.1002164.ref005" ref-type="bibr">5</xref>,<xref rid="pbio.1002164.ref006" ref-type="bibr">6</xref>], in which companies improve their competitiveness by entering into open external partnerships. However, Open Innovation appears to have had very little impact on the trajectory of drug discovery, presumably because such partnerships most often only involve inward flow of knowledge or exclusive exchanges between a limited number of partners. On occasion, they involve outflow of assets, but these assets are typically restricted to a few appointed groups and with strings attached. Open Innovation as exercised above is an advance, but its true impact remains to be seen.</p>
<p>On the other hand, there are several initiatives in the biomedical research area that are true to the public’s understanding of the term “open” and that practice a genuine open access or open source and precompetitive scientific commons approach. These projects appear to have had significant impact, and some have been transformational, including the Single Nucleotide Polymorphisms Consortium (1999; [<xref rid="pbio.1002164.ref007" ref-type="bibr">7</xref>]), the International HapMap Project (2002; [<xref rid="pbio.1002164.ref008" ref-type="bibr">8</xref>]), the Open Source Malaria Project (2011; [<xref rid="pbio.1002164.ref009" ref-type="bibr">9</xref>]), and the Structural Genomics Consortium (SGC) (2003; [<xref rid="pbio.1002164.ref010" ref-type="bibr">10</xref>]; <ext-link ext-link-type="uri" xlink:href="http://www.thesgc.org" xlink:type="simple">www.thesgc.org</ext-link>).</p>
<p>It is important to reiterate that drug discovery is a long and intricate process with different types of challenges and thus different approaches. In the early hypothesis generation stages, it makes sense for different communities to join efforts to create novel, open research tools that can be used by everyone [<xref rid="pbio.1002164.ref011" ref-type="bibr">11</xref>]. This is in contrast to late, derisked stages, where different groups can begin development of their own proprietary products [<xref rid="pbio.1002164.ref012" ref-type="bibr">12</xref>]. As such, we will be examining the impact of open access in early stages of drug discovery, especially in target discovery and validation, as these are strong indicators of success in creating new medicines.</p>
</sec>
<sec id="sec002">
<title>Open Access to Eliminate Choke Points in Early Target Discovery</title>
<p>The SGC was formed in 2003 with the open access ethos as its core tenet and has since catalysed research in new areas of human biology and drug discovery by focusing to a large extent on less well-studied areas of human biology and disease. The SGC, strongly supported by its pharmaceutical industry partners, places all its research output and reagents, including industry-standard small molecule chemical inhibitors (probes) in the public domain without restriction on use. These are used widely to interrogate protein targets and signalling pathways to further our understanding of disease mechanisms, for instance.</p>
<p>The establishment of a precompetitive and patent-free consortium has had many advantages; some were obvious and others unexpected. What was clear at the outset was that adhering to open access principles allowed cross-leveraging of public and private funds to explore novel areas of human biology in an organised way, thus reducing duplication and sharing the risks and costs that no single institution could bear alone. It was also clear that it would place the emphasis on the science and on accelerating the transfer of knowledge to the scientific community, rather than on commercial interests. The SGC has disseminated tens of thousands of cDNA clones and thousands of samples of several chemical inhibitors, with hardly any transactional costs. Hundreds of academic papers report the use of SGC-generated reagents, and across the pharmaceutical and biotechnology sectors, SGC reagents are used daily to advance internal drug discovery programs.</p>
<p>What was less appreciated was the extent to which the consortium’s position would resonate with the academic and clinical communities. The SGC collaborative network now comprises of scientists in hundreds of institutions around the world—all of whom have committed to the open access principles and who contribute their ideas and results to the public domain. The value of this collaborative network and of the network of academics making discoveries with SGC chemical probes is difficult to quantify, but a rough comparator is the fact that industry typically budgets hundreds of thousands of dollars to fund and manage even a single collaboration. Given that the SGC collaborates with over 300 different laboratories and has disseminated over 4,000 samples of chemical probes so far, one may argue that its open-access network provides hundreds of millions of dollars of value.</p>
</sec>
<sec id="sec003">
<title>Open Access Drives Faster Pioneering Science</title>
<p>Epigenetics is an exciting area of biology that has gained a large degree of attention over the last few years, holding a vast potential for drug discovery [<xref rid="pbio.1002164.ref013" ref-type="bibr">13</xref>]. However, despite there being more than 400 proteins known to be involved in epigenetic regulation [<xref rid="pbio.1002164.ref014" ref-type="bibr">14</xref>], as of 2010, only one target family, histone deacetylases (HDACs), comprised of more than 20 proteins, had been targeted by cell active inhibitors in the public domain.</p>
<p>Appreciating that the other proteins and protein families implicated in epigenetic regulation were likely important, in 2005, the SGC began to purify them and solve their 3-D structures. In 2009, after having made significant progress, GlaxoSmithKline (GSK) approached SGC with the “outside-the-box” idea to design highly-potent, highly-selective inhibitors of these proteins using structure-guided methods and to provide them to the community without restrictions. The concept was that these probes would be rapidly used by the community to help define the roles of the proteins in human biology, as exemplified by past experiences with similar approaches in the field of probes for nuclear receptors [<xref rid="pbio.1002164.ref011" ref-type="bibr">11</xref>]. With funding from the Wellcome Trust and the Ontario government, and medicinal chemistry expertise from industrial partners, the project was launched and focused on underexplored protein families such as lysine demethylases (KDMs; [<xref rid="pbio.1002164.ref015" ref-type="bibr">15</xref>–<xref rid="pbio.1002164.ref019" ref-type="bibr">19</xref>]), histone methyltransferases (HMTs; [<xref rid="pbio.1002164.ref020" ref-type="bibr">20</xref>–<xref rid="pbio.1002164.ref024" ref-type="bibr">24</xref>]), and Bromodomains [<xref rid="pbio.1002164.ref025" ref-type="bibr">25</xref>–<xref rid="pbio.1002164.ref027" ref-type="bibr">27</xref>] (full list of SGC probes: <ext-link ext-link-type="uri" xlink:href="http://www.thesgc.org/chemical-probes/epigenetics" xlink:type="simple">www.thesgc.org/chemical-probes/epigenetics</ext-link>).</p>
<p>The open access model provided the framework to receive invaluable advice from scientists at GSK about the bromodomains protein family. Based on insights from GSK scientists, we initiated a collaboration on the role of the BRD4 bromodomain in NUT midline carcinoma—an incurable rare cancer. Within 11 months, a small molecule called SGCBD01 (aka JQ1) was designed, synthesised, and used to show that inhibition of BDR4 promoted both differentiation and apoptosis of patient-derived primary cells [<xref rid="pbio.1002164.ref028" ref-type="bibr">28</xref>,<xref rid="pbio.1002164.ref029" ref-type="bibr">29</xref>].</p>
<p>The rapid progress made with bromodomains is a testament to the power of open access, but the true value of open science emerged once SGCBD01 or JQ1 and additional probes by GSK (I-BET) [<xref rid="pbio.1002164.ref030" ref-type="bibr">30</xref>] and Pfizer (PFI-1) [<xref rid="pbio.1002164.ref031" ref-type="bibr">31</xref>] were distributed to the community. Within half a year, these compounds were used by the community to link bromodomains to septic shock [<xref rid="pbio.1002164.ref030" ref-type="bibr">30</xref>], leukaemia [<xref rid="pbio.1002164.ref032" ref-type="bibr">32</xref>,<xref rid="pbio.1002164.ref033" ref-type="bibr">33</xref>], multiple myeloma [<xref rid="pbio.1002164.ref034" ref-type="bibr">34</xref>], cardiac hypertrophy [<xref rid="pbio.1002164.ref035" ref-type="bibr">35</xref>,<xref rid="pbio.1002164.ref036" ref-type="bibr">36</xref>], HIV infection [<xref rid="pbio.1002164.ref034" ref-type="bibr">34</xref>,<xref rid="pbio.1002164.ref037" ref-type="bibr">37</xref>,<xref rid="pbio.1002164.ref038" ref-type="bibr">38</xref>], and MYC regulation [<xref rid="pbio.1002164.ref034" ref-type="bibr">34</xref>,<xref rid="pbio.1002164.ref038" ref-type="bibr">38</xref>].</p>
</sec>
<sec id="sec004">
<title>Open Access Generates Pioneering Drug Programmes and Clinical Studies Quicker—for Everyone</title>
<p>Discoveries based on the use of small molecule probes are highly valued by industry and academia, and experience shows that availability of potent, specific, drug-like chemical compounds (probes) increases the chances of final success in drug discovery programs [<xref rid="pbio.1002164.ref011" ref-type="bibr">11</xref>]. The probes enable the definition and validation of targets and pathways, using experimental systems that resemble final and approved therapeutic modalities, in its cellular context [<xref rid="pbio.1002164.ref039" ref-type="bibr">39</xref>]. The aim of the SGC in producing open-access chemical probes was to spur and accelerate innovative drug discovery (<xref rid="pbio.1002164.g001" ref-type="fig">Fig 1</xref>). The breadth, depth, and reproducibility of numerous studies enabled by high-quality BET bromodomains chemical probes led to the registration of the first clinical trial aimed at this class of proteins by GSK in April 2012 (Clinical Trial Registration: NCT01587703), 16 months after the seminal publication on targeting BRD4 histone reader with SGCBD01 or JQ1 (28). Currently, there are twelve clinical trials with BET bromodomains inhibitors registered (<xref rid="pbio.1002164.t001" ref-type="table">Table 1</xref>).</p>
<fig id="pbio.1002164.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.1002164.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Open science accelerates identification of the best targets and drug indications, in the correct patient population.</title>
<p>The Closed (upper half) model is compared to the Open (lower half) model; the availability of open access chemical tools for novel proteins and the freedom to operate enable the global community to explore different indications and diseases in parallel and quickly share back through publications. The breadth and depth of the studies in the open model lower the risks of failure in subsequent stages in a typical drug discovery programme, allowing the scientists to focus on the most promising indications, whilst reducing the level of effort (open squares), wastage, and duplication engendered by secrecy of the closed models.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pbio.1002164.g001" position="float" xlink:type="simple"/>
</fig>
<table-wrap id="pbio.1002164.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.1002164.t001</object-id>
<label>Table 1</label> <caption><title>Clinical trials targeting bromodomains and registered on ClinicalTrials.gov (National Library of Medicine and National Institutes of Health, United States), as of 1 January 2015.</title></caption>
<alternatives>
<graphic id="pbio.1002164.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pbio.1002164.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">NCT Number</th>
<th align="left" rowspan="1" colspan="1">Title</th>
<th align="left" rowspan="1" colspan="1">Conditions</th>
<th align="left" rowspan="1" colspan="1">Molecule</th>
<th align="left" rowspan="1" colspan="1">Sponsor or Collaborators</th>
<th align="left" rowspan="1" colspan="1">Phases</th>
<th align="left" rowspan="1" colspan="1">First Received</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT01587703</bold></td>
<td align="left" rowspan="1" colspan="1">A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers</td>
<td align="left" rowspan="1" colspan="1">Carcinoma, midline</td>
<td align="left" rowspan="1" colspan="1">Drug: GSK525762</td>
<td align="left" rowspan="1" colspan="1">GlaxoSmithKline</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">3 April 2012</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT01713582</bold></td>
<td align="left" rowspan="1" colspan="1">A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015 in Haematological Malignancies</td>
<td align="left" rowspan="1" colspan="1">Acute leukaemia, other hematological malignacies</td>
<td align="left" rowspan="1" colspan="1">Drug: OTX015</td>
<td align="left" rowspan="1" colspan="1">OncoEthix</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">22 October 2012</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT01949883</bold></td>
<td align="left" rowspan="1" colspan="1">A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma</td>
<td align="left" rowspan="1" colspan="1">Lymphoma</td>
<td align="left" rowspan="1" colspan="1">Drug: CPI-0610</td>
<td align="left" rowspan="1" colspan="1">Constellation Pharmaceuticals, The Leukaemia and Lymphoma Society</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">10 September 2013</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT01987362</bold></td>
<td align="left" rowspan="1" colspan="1">A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously</td>
<td align="left" rowspan="1" colspan="1">Solid tumors</td>
<td align="left" rowspan="1" colspan="1">Drug: TEN-010</td>
<td align="left" rowspan="1" colspan="1">Tensha Therapeutics</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">5 November 2013</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT02157636</bold></td>
<td align="left" rowspan="1" colspan="1">A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma</td>
<td align="left" rowspan="1" colspan="1">Multiple myeloma</td>
<td align="left" rowspan="1" colspan="1">Drug: CPI-0610</td>
<td align="left" rowspan="1" colspan="1">Constellation Pharmaceutical, The Leukaemia and Lymphoma Society</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">28 May 2014</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT02158858</bold></td>
<td align="left" rowspan="1" colspan="1">A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukaemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms</td>
<td align="left" rowspan="1" colspan="1">Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)</td>
<td align="left" rowspan="1" colspan="1">Drug: CPI-0610</td>
<td align="left" rowspan="1" colspan="1">Constellation Pharmaceuticals, The Leukaemia and Lymphoma Society</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">5 Jun 2014</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT02259114</bold></td>
<td align="left" rowspan="1" colspan="1">A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors</td>
<td align="left" rowspan="1" colspan="1">NUT midline carcinoma, triple negative breast cancer, non-small cell lung cancer with rearranged ALK gene/fusion protein or KRAS mutation, Castrate-resistant Prostate Cancer (CRPC), pancreatic ductal adenocarcinoma</td>
<td align="left" rowspan="1" colspan="1">Drug: OTX015</td>
<td align="left" rowspan="1" colspan="1">OncoEthix</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">3 October 2014</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT02296476</bold></td>
<td align="left" rowspan="1" colspan="1">A Trial With Dose Optimization of OTX015 in Recurrent Glioblastoma Multiforme (GBM) Patients</td>
<td align="left" rowspan="1" colspan="1">Glioblastoma ultiforme</td>
<td align="left" rowspan="1" colspan="1">Drug: OTX015</td>
<td align="left" rowspan="1" colspan="1">OncoEthix</td>
<td align="left" rowspan="1" colspan="1">Phase 1 Phase 2</td>
<td align="left" rowspan="1" colspan="1">3 October 2014</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT02303782</bold></td>
<td align="left" rowspan="1" colspan="1">A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukaemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)</td>
<td align="left" rowspan="1" colspan="1">AML</td>
<td align="left" rowspan="1" colspan="1">Drug: OTX015, Drug: Vidaza (azacitidine)</td>
<td align="left" rowspan="1" colspan="1">OncoEthix</td>
<td align="left" rowspan="1" colspan="1">Phase 1 Phase 2</td>
<td align="left" rowspan="1" colspan="1">24 November 2014</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT02308761</bold></td>
<td align="left" rowspan="1" colspan="1">A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome</td>
<td align="left" rowspan="1" colspan="1">AML, MDS</td>
<td align="left" rowspan="1" colspan="1">Drug: TEN-010</td>
<td align="left" rowspan="1" colspan="1">Tensha Therapeutics</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">14 November 2014</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT02369029</bold></td>
<td align="left" rowspan="1" colspan="1">An Open-label, Non-randomized, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1238097 in Subjects With Advanced Malignancies</td>
<td align="left" rowspan="1" colspan="1">Neoplasms</td>
<td align="left" rowspan="1" colspan="1">Drug: BAY1238097</td>
<td align="left" rowspan="1" colspan="1">Bayer</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">17 February 2015</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>NCT02391480</bold></td>
<td align="left" rowspan="1" colspan="1">A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer</td>
<td align="left" rowspan="1" colspan="1">Advanced cancer, breast cancer, non-small cell lung cancer, AML, multiple myeloma</td>
<td align="left" rowspan="1" colspan="1">Drug: ABBV-075</td>
<td align="left" rowspan="1" colspan="1">AbbVie</td>
<td align="left" rowspan="1" colspan="1">Phase 1</td>
<td align="left" rowspan="1" colspan="1">12 March 2015</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>It is interesting to note that until early 2015, nine out of ten trials (GSK’s being the exception) were registered by either a small biotech or start-up company. In one notable example, the clinical candidate (CPI-0610) used in three different trials was developed in partnership with a nonprofit, patient-driven organisation—The Leukaemia and Lymphoma Society. As such, one could argue that the open model is challenging the established system by enabling a wider range of groups to easily and quickly access innovation. This leads to a more efficient route to attract incentives and rewards, especially in the fragile interstice of “valley of death” in drug discovery.</p>
</sec>
<sec id="sec005">
<title>Open Access Invigorating Patient-Driven Research—The Most Transformative Impact</title>
<p>The open access model has had system-wide impact in biomedical science and drug discovery. This is tremendously exciting, but what we are now interested in exploring is whether we can make a much bigger impact if the open access model is combined with the determination and focus of patient-driven initiatives.</p>
<p>Open access initiatives and patient and disease foundations share a common focus—to advance science toward a cure. For most patients and their families, issues of ownership and profit are irrelevant. This holds especially true for foundations of untreatable or rare conditions such as <italic>Fibrodysplasia Ossificans Progressiva</italic> (FOP; “Stone Man Syndrome”) and Adult Polyglucosan Body Disease (APBD).</p>
<p>Could marrying the SGC open-access approach to drug discovery with the dedication and focus of disease foundations result in faster advances? We believe so.</p>
<p>FOP United Kingdom, the foundation supporting research into FOP, worked with the SGC and its collaborative network on structure-based development of inhibitors for ACVR1, a kinase for which specific mutation has been identified of the disease [<xref rid="pbio.1002164.ref040" ref-type="bibr">40</xref>,<xref rid="pbio.1002164.ref041" ref-type="bibr">41</xref>], as well as for the understanding of mutant phenotypes [<xref rid="pbio.1002164.ref042" ref-type="bibr">42</xref>]. Molecules from this partnership are now being optimised for future clinical studies.</p>
<p>Most recently, the SGC and CHDI Foundation have teamed up to discover and characterise new drug targets for Huntington’s disease (HD). In this first partnership of its kind, both have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction [<xref rid="pbio.1002164.ref043" ref-type="bibr">43</xref>]. This is a pioneering move by CHDI and establishes a template for how patient-orientated funders can help the research community develop new drugs—in fact, the Ontario Brain Institute has already entered into a similar agreement with the SGC, to further research on Rett’s syndrome.</p>
<p>Finally, participation of patients and disease foundations is also pivotal for the establishment of anonymised primary cell and tissue open platforms. This will accelerate generation of robust, clinically meaningful assays to profile molecularly-targeted probes using phenotypic and biomarker readouts linking novel targets to new indications [<xref rid="pbio.1002164.ref039" ref-type="bibr">39</xref>].</p>
</sec>
<sec id="sec006">
<title>Open Access and Potential Pitfalls</title>
<p>One curious behaviour is that the scientific community has been giving a disproportionately large focus on earlier tools rather than exploring other open probes available so far, probably reflecting the established risk aversion we encounter in biomedical research [<xref rid="pbio.1002164.ref044" ref-type="bibr">44</xref>]. Therefore, even though open access can accelerate investigation of novel biology, it is important for the community to be aware of this trend and to cover more efficiently all the novel tools and target areas that are being enabled by open initiatives.</p>
</sec>
<sec id="sec007">
<title>Expanding the Open Access Ecosystem</title>
<p>The main tenets of precompetitive, patent-free and open-access research have enabled the establishment of a new dynamic ecosystem, not confined to biomedicine alone. The open access ethos ensures a high degree of crosstalk between sectors, including more than 300 academic groups, government agencies, biotech companies, start-ups, entrepreneurs, lawyers, economists, social scientists, and patients, all working together to expand the impact of open access drug discovery (<xref rid="pbio.1002164.s001" ref-type="supplementary-material">S1 Fig</xref>). The last ten years have been exciting and rewarding with a future that looks bright and even more promising—for science, for patients, and for society as a whole; what are you waiting for? Join us!</p>
</sec>
<sec id="sec008">
<title>Supporting Information</title>
<supplementary-material id="pbio.1002164.s001" xlink:href="info:doi/10.1371/journal.pbio.1002164.s001" mimetype="image/tiff" position="float" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>The SGC super network.</title>
<p>The SGC’s Open Access model is transformative and encourages crossfields, cross-sector interactions to accelerate drug discovery and advancement of basic biology. This has resulted in the establishment of a network of collaborations and projects, covering a wide range of initiatives implemented alongside strategic partners. For a full overview of the SGC’s scientific coverage, please refer to <ext-link ext-link-type="uri" xlink:href="http://www.thesgc.org" xlink:type="simple">www.thesgc.org</ext-link>.</p>
<p><bold>• Human tissue platforms and Inflammation</bold>: exploring biology of novel proteins using patient-derived primary cells and tissues.</p>
<p><bold>• Target Enabling Packages (TEPs)</bold>: generating open access “toolkits” (structures, assays, proteins, chemical starting points, etc.) to allow exploration of novel, genetically validated targets.</p>
<p><bold>• Structural parasitology &amp; neglected diseases</bold>: using structure-based methodologies and science to advance development of novel treatments [<ext-link ext-link-type="uri" xlink:href="http://www.thesgc.org/sddc" xlink:type="simple">http://www.thesgc.org/sddc</ext-link>].</p>
<p><bold>• Rare diseases</bold>: expanding the understanding of structure and function of the associated proteins as well as the effects of disease mutations [<ext-link ext-link-type="uri" xlink:href="http://www.thesgc.org/science/rare-diseases" xlink:type="simple">http://www.thesgc.org/science/rare-diseases</ext-link>].</p>
<p><bold>• Patient &amp; disease foundations</bold>: working together with focused networks of disease specialists to further increase knowledge in structural biology and functional and chemical spaces around implicated proteins [Dolgin, Nat Med 2014].</p>
<p><bold>• Kinase inhibitors for human &amp; plant sciences</bold>: facilitating the cross-sector use of open-access chemical probes targeting basic biology [Knapp et al., Nat Chem Biol 2013].</p>
<p><bold>• Open clinical proof-of-concept</bold>: expanding the precompetitive, patent-free model towards phase II clinical proof-of-concept [Norman et al., Sci Transl Med 2011a, 2011b].</p>
<p><bold>• Start-ups &amp; incubators</bold>: creation of open access toolkits for pioneer biology and dynamic entrepreneurial communities have already resulted in creation of independent start-ups.</p>
<p><bold>• Ethics &amp; economics</bold>: open-access model has created new paradigms around the philosophy and practical and economic aspects of discovering novel treatments and medicines.</p>
<p><bold>• Governments &amp; policymakers:</bold> availability of a model that can expedite drug discovery and reduce its cost is of interest for governments, always under pressure to address societal healthcare needs.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The author would like to thank Aled Edwards, Chas Bountra, Cheryl Arrowsmith, and Michael Sundstrom for their guidance and critical review of this manuscript, all SGC colleagues in Oxford, Toronto, Stockholm, and Campinas for their friendly support, and our network of collaborators for their unabated enthusiasm in supporting open access.</p>
</ack>
<glossary>
<title>Abbreviations:</title>
<def-list>
<def-item><term>AML</term>
<def><p>Acute Myeloid Leukaemia</p></def>
</def-item>
<def-item><term>APBD</term>
<def><p>Adult Polyglucoson Body Disease</p></def>
</def-item>
<def-item><term>CRPC</term>
<def><p>Castrate-resistant Prostate Cancer</p></def>
</def-item>
<def-item><term>FOP</term>
<def><p>Fibrodysplasia Ossificans Progressiva</p></def>
</def-item>
<def-item><term>GSK</term>
<def><p>GlaxoSmithKline</p></def>
</def-item>
<def-item><term>HD</term>
<def><p>Huntington’s disease</p></def>
</def-item>
<def-item><term>HDAC</term>
<def><p>histone deacetylase</p></def>
</def-item>
<def-item><term>HMT</term>
<def><p>histone methyltransferase</p></def>
</def-item>
<def-item><term>KDM</term>
<def><p>lysine demethylase</p></def>
</def-item>
<def-item><term>MDS</term>
<def><p>Myelodysplastic Syndrome</p></def>
</def-item>
<def-item><term>MPN</term>
<def><p>Myeloproliferative Neoplasms</p></def>
</def-item>
<def-item><term>R &amp; D</term>
<def><p>research and development</p></def>
</def-item>
<def-item><term>SGC</term>
<def><p>Structural Genomics Consortium</p></def>
</def-item>
<def-item><term>TEP</term>
<def><p>Target Enabling Packages</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pbio.1002164.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Munos</surname> <given-names>B</given-names></name>. <article-title>Lessons from 60 years of pharmaceutical innovation</article-title>. <source>Nat Rev Drug Discov</source>. <year>2009</year> <month>Dec</month>;<volume>8</volume>(<issue>12</issue>):<fpage>959</fpage>–<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd2961" xlink:type="simple">10.1038/nrd2961</ext-link></comment> <object-id pub-id-type="pmid">19949401</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bunnage</surname> <given-names>ME</given-names></name>. <article-title>Getting pharmaceutical R&amp;D back on target</article-title>. <source>Nat Chem Biol</source>. <year>2011</year> <month>Jun</month>;<volume>7</volume>(<issue>6</issue>):<fpage>335</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nchembio.581" xlink:type="simple">10.1038/nchembio.581</ext-link></comment> <object-id pub-id-type="pmid">21587251</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abrams</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Stevens</surname> <given-names>AJ</given-names></name>. <article-title>How are U.S. technology transfer offices tasked and motivated: is it all about the money?</article-title> <source>Research Management Review</source>. <year>2009</year>;<volume>17</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>34</lpage>.</mixed-citation></ref>
<ref id="pbio.1002164.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heller</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Eisenberg</surname> <given-names>RS</given-names></name>. <article-title>Can patents deter innovation? The anticommons in biomedical research</article-title>. <source>Science</source>. <year>1998</year> <month>May</month> <day>1</day>;<volume>280</volume>(<issue>5364</issue>):<fpage>698</fpage>–<lpage>701</lpage>. <object-id pub-id-type="pmid">9563938</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chesbrough</surname> <given-names>H</given-names></name>. <article-title>The logic of open innovation: Managing intellectual property</article-title>. <source>Calif Manage Rev</source>. <year>2003</year> Spr;<volume>45</volume>(<issue>3</issue>):<fpage>33</fpage>-+.</mixed-citation></ref>
<ref id="pbio.1002164.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chesbrough</surname> <given-names>HW</given-names></name>. <article-title>The era of open innovation</article-title>. <source>Mit Sloan Manage Rev</source>. <year>2003</year> Spr;<volume>44</volume>(<issue>3</issue>):<fpage>35</fpage>–<lpage>41</lpage>.</mixed-citation></ref>
<ref id="pbio.1002164.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sachidanandam</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Weissman</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Schmidt</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Kakol</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Stein</surname> <given-names>LD</given-names></name>, <name name-style="western"><surname>Marth</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms</article-title>. <source>Nature</source>. <year>2001</year> <month>Feb</month> <day>15</day>;<volume>409</volume>(<issue>6822</issue>):<fpage>928</fpage>–<lpage>33</lpage>. <object-id pub-id-type="pmid">11237013</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><article-title>The International HapMap Project</article-title>. <source>Nature</source>. <year>2003</year> <month>Dec</month> <day>18</day>;<volume>426</volume>(<issue>6968</issue>):<fpage>789</fpage>–<lpage>96</lpage>. <object-id pub-id-type="pmid">14685227</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Robertson</surname> <given-names>MN</given-names></name>, <name name-style="western"><surname>Ylioja</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Williamson</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Woelfle</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Robins</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Badiola</surname> <given-names>KA</given-names></name>, <etal>et al</etal>. <article-title>Open source drug discovery—a limited tutorial</article-title>. <source>Parasitology</source>. <year>2014</year> <month>Jan</month>;<volume>141</volume>(<issue>1</issue>):<fpage>148</fpage>–<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1017/S0031182013001121" xlink:type="simple">10.1017/S0031182013001121</ext-link></comment> <object-id pub-id-type="pmid">23985301</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gileadi</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Knapp</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>WH</given-names></name>, <name name-style="western"><surname>Marsden</surname> <given-names>BD</given-names></name>, <name name-style="western"><surname>Muller</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Niesen</surname> <given-names>FH</given-names></name>, <etal>et al</etal>. <article-title>The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins</article-title>. <source>J Struct Funct Genomics</source>. <year>2007</year> <month>Sep</month>;<volume>8</volume>(<issue>2–3</issue>):<fpage>107</fpage>–<lpage>19</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10969-007-9038-z" xlink:type="simple">10.1007/s10969-007-9038-z</ext-link></comment> <object-id pub-id-type="pmid">18167031</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Edwards</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Bountra</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kerr</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Willson</surname> <given-names>TM</given-names></name>. <article-title>Open access chemical and clinical probes to support drug discovery</article-title>. <source>Nat Chem Biol</source>. <year>2009</year> <month>Jul</month>;<volume>5</volume>(<issue>7</issue>):<fpage>436</fpage>–<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nchembio0709-436" xlink:type="simple">10.1038/nchembio0709-436</ext-link></comment> <object-id pub-id-type="pmid">19536100</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weigelt</surname> <given-names>J</given-names></name>. <article-title>The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery</article-title>. <source>EMBO Rep</source>. <year>2009</year> <month>Sep</month>;<volume>10</volume>(<issue>9</issue>):<fpage>941</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/embor.2009.193" xlink:type="simple">10.1038/embor.2009.193</ext-link></comment> <object-id pub-id-type="pmid">19721463</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Liang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Aparicio</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>PA</given-names></name>. <article-title>Epigenetics in human disease and prospects for epigenetic therapy</article-title>. <source>Nature</source>. <year>2004</year> <month>May</month> <day>27</day>;<volume>429</volume>(<issue>6990</issue>):<fpage>457</fpage>–<lpage>63</lpage>. <object-id pub-id-type="pmid">15164071</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arrowsmith</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Bountra</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fish</surname> <given-names>PV</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Schapira</surname> <given-names>M</given-names></name>. <article-title>Epigenetic protein families: a new frontier for drug discovery</article-title>. <source>Nat Rev Drug Discov</source>. <year>2012</year> <month>May</month>;<volume>11</volume>(<issue>5</issue>):<fpage>384</fpage>–<lpage>400</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd3674" xlink:type="simple">10.1038/nrd3674</ext-link></comment> <object-id pub-id-type="pmid">22498752</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Walport</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Hopkinson</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Vollmar</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Madden</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Gileadi</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Oppermann</surname> <given-names>U</given-names></name>, <etal>et al</etal>. <article-title>Human UTY(KDM6C) is a male-specific N-methyl lysyl demethylase</article-title>. <source>J Biol Chem</source>. <year>2014</year> <month>Jun</month> <day>27</day>;<volume>289</volume>(<issue>26</issue>):<fpage>18302</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M114.555052" xlink:type="simple">10.1074/jbc.M114.555052</ext-link></comment> <object-id pub-id-type="pmid">24798337</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kruidenier</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Liddle</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Che</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Joberty</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response</article-title>. <source>Nature</source>. <year>2012</year> <month>Aug</month> <day>16</day>;<volume>488</volume>(<issue>7411</issue>):<fpage>404</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature11262" xlink:type="simple">10.1038/nature11262</ext-link></comment> <object-id pub-id-type="pmid">22842901</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hillringhaus</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Yue</surname> <given-names>WW</given-names></name>, <name name-style="western"><surname>Rose</surname> <given-names>NR</given-names></name>, <name name-style="western"><surname>Ng</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Gileadi</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Loenarz</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family</article-title>. <source>J Biol Chem</source>. <year>2011</year> <month>Dec</month> <day>2</day>;<volume>286</volume>(<issue>48</issue>):<fpage>41616</fpage>–<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M111.283689" xlink:type="simple">10.1074/jbc.M111.283689</ext-link></comment> <object-id pub-id-type="pmid">21914792</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>King</surname> <given-names>ON</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>XS</given-names></name>, <name name-style="western"><surname>Sakurai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kawamura</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rose</surname> <given-names>NR</given-names></name>, <name name-style="western"><surname>Ng</surname> <given-names>SS</given-names></name>, <etal>et al</etal>. <article-title>Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>11</issue>):<fpage>e15535</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0015535" xlink:type="simple">10.1371/journal.pone.0015535</ext-link></comment> <object-id pub-id-type="pmid">21124847</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rose</surname> <given-names>NR</given-names></name>, <name name-style="western"><surname>Ng</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Mecinovic</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lienard</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Bello</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases</article-title>. <source>J Med Chem</source>. <year>2008</year> <month>Nov</month> <day>27</day>;<volume>51</volume>(<issue>22</issue>):<fpage>7053</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/jm800936s" xlink:type="simple">10.1021/jm800936s</ext-link></comment> <object-id pub-id-type="pmid">18942826</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siarheyeva</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Senisterra</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Allali-Hassani</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Dong</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Dobrovetsky</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Wasney</surname> <given-names>GA</given-names></name>, <etal>et al</etal>. <article-title>An allosteric inhibitor of protein arginine methyltransferase 3</article-title>. <source>Structure</source>. <year>2012</year> <month>Aug</month> <day>8</day>;<volume>20</volume>(<issue>8</issue>):<fpage>1425</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.str.2012.06.001" xlink:type="simple">10.1016/j.str.2012.06.001</ext-link></comment> <object-id pub-id-type="pmid">22795084</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vedadi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Barsyte-Lovejoy</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Rival-Gervier</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Allali-Hassani</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Labrie</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells</article-title>. <source>Nat Chem Biol</source>. <year>2011</year> <month>Aug</month>;<volume>7</volume>(<issue>8</issue>):<fpage>566</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nchembio.599" xlink:type="simple">10.1038/nchembio.599</ext-link></comment> <object-id pub-id-type="pmid">21743462</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Min</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lunin</surname> <given-names>VV</given-names></name>, <name name-style="western"><surname>Antoshenko</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Dombrovski</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Zeng</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Structural biology of human H3K9 methyltransferases</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>1</issue>):<fpage>e8570</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0008570" xlink:type="simple">10.1371/journal.pone.0008570</ext-link></comment> <object-id pub-id-type="pmid">20084102</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yu</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Chory</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Wernimont</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Tempel</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Scopton</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Federation</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors</article-title>. <source>Nat Commun</source>. <year>2012</year>;<volume>3</volume>:<fpage>1288</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms2304" xlink:type="simple">10.1038/ncomms2304</ext-link></comment> <object-id pub-id-type="pmid">23250418</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Senisterra</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Allali-Hassani</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wasney</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Barsyte-Lovejoy</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Dombrovski</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5</article-title>. <source>Biochem J</source>. <year>2013</year> <month>Jan</month> <day>1</day>;<volume>449</volume>(<issue>1</issue>):<fpage>151</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/BJ20121280" xlink:type="simple">10.1042/BJ20121280</ext-link></comment> <object-id pub-id-type="pmid">22989411</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Muller</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Filippakopoulos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Knapp</surname> <given-names>S</given-names></name>. <article-title>Bromodomains as therapeutic targets</article-title>. <source>Expert Rev Mol Med</source>. <year>2011</year> <month>Sep</month> <day>13</day>;<volume>13</volume>:<fpage>1</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="pbio.1002164.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Filippakopoulos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Knapp</surname> <given-names>S</given-names></name>. <article-title>The bromodomain interaction module</article-title>. <source>Febs Lett</source>. <year>2012</year> <month>Aug</month> <day>14</day>;<volume>586</volume>(<issue>17</issue>):<fpage>2692</fpage>–<lpage>704</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.febslet.2012.04.045" xlink:type="simple">10.1016/j.febslet.2012.04.045</ext-link></comment> <object-id pub-id-type="pmid">22710155</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Filippakopoulos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Knapp</surname> <given-names>S</given-names></name>. <article-title>Targeting bromodomains: epigenetic readers of lysine acetylation</article-title>. <source>Nat Rev Drug Discov</source>. <year>2014</year> <month>May</month>;<volume>13</volume>(<issue>5</issue>):<fpage>337</fpage>–<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd4286" xlink:type="simple">10.1038/nrd4286</ext-link></comment> <object-id pub-id-type="pmid">24751816</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Filippakopoulos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Qi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Picaud</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>WB</given-names></name>, <name name-style="western"><surname>Fedorov</surname> <given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Selective inhibition of BET bromodomains</article-title>. <source>Nature</source>. <year>2010</year> <month>Dec</month> <day>23</day>;<volume>468</volume>(<issue>7327</issue>):<fpage>1067</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature09504" xlink:type="simple">10.1038/nature09504</ext-link></comment> <object-id pub-id-type="pmid">20871596</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Taverna</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Cole</surname> <given-names>PA</given-names></name>. <article-title>Drug discovery: Reader's block</article-title>. <source>Nature</source>. <year>2010</year> <month>Dec</month> <day>23</day>;<volume>468</volume>(<issue>7327</issue>):<fpage>1050</fpage>–<lpage>1</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/4681050a" xlink:type="simple">10.1038/4681050a</ext-link></comment> <object-id pub-id-type="pmid">21179160</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nicodeme</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Jeffrey</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Schaefer</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Beinke</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dewell</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>CW</given-names></name>, <etal>et al</etal>. <article-title>Suppression of inflammation by a synthetic histone mimic</article-title>. <source>Nature</source>. <year>2010</year> <month>Dec</month> <day>23</day>;<volume>468</volume>(<issue>7327</issue>):<fpage>1119</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature09589" xlink:type="simple">10.1038/nature09589</ext-link></comment> <object-id pub-id-type="pmid">21068722</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Picaud</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Da Costa</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Thanasopoulou</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Filippakopoulos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Fish</surname> <given-names>PV</given-names></name>, <name name-style="western"><surname>Philpott</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains</article-title>. <source>Cancer Res</source>. <year>2013</year> <month>Jun</month> <day>1</day>;<volume>73</volume>(<issue>11</issue>):<fpage>3336</fpage>–<lpage>46</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-12-3292" xlink:type="simple">10.1158/0008-5472.CAN-12-3292</ext-link></comment> <object-id pub-id-type="pmid">23576556</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Blobel</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Kalota</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sanchez</surname> <given-names>PV</given-names></name>, <name name-style="western"><surname>Carroll</surname> <given-names>M</given-names></name>. <article-title>Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia</article-title>. <source>Cancer Cell</source>. <year>2011</year> <month>Sep</month> <day>13</day>;<volume>20</volume>(<issue>3</issue>):<fpage>287</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccr.2011.08.019" xlink:type="simple">10.1016/j.ccr.2011.08.019</ext-link></comment> <object-id pub-id-type="pmid">21907920</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zuber</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Rappaport</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Herrmann</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sison</surname> <given-names>EA</given-names></name>, <etal>et al</etal>. <article-title>RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia</article-title>. <source>Nature</source>. <year>2011</year> <month>Oct</month> <day>27</day>;<volume>478</volume>(<issue>7370</issue>):<fpage>524</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature10334" xlink:type="simple">10.1038/nature10334</ext-link></comment> <object-id pub-id-type="pmid">21814200</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Delmore</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Issa</surname> <given-names>GC</given-names></name>, <name name-style="western"><surname>Lemieux</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Rahl</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jacobs</surname> <given-names>HM</given-names></name>, <etal>et al</etal>. <article-title>BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title>. <source>Cell</source>. <year>2011</year> <month>Sep</month> <day>16</day>;<volume>146</volume>(<issue>6</issue>):<fpage>904</fpage>–<lpage>17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2011.08.017" xlink:type="simple">10.1016/j.cell.2011.08.017</ext-link></comment> <object-id pub-id-type="pmid">21889194</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spiltoir</surname> <given-names>JI</given-names></name>, <name name-style="western"><surname>Stratton</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Cavasin</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Demos-Davies</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Reid</surname> <given-names>BG</given-names></name>, <name name-style="western"><surname>Qi</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>BET acetyl-lysine binding proteins control pathological cardiac hypertrophy</article-title>. <source>J Mol Cell Cardiol</source>. <year>2013</year> <month>Oct</month>;<volume>63</volume>:<fpage>175</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2013.07.017" xlink:type="simple">10.1016/j.yjmcc.2013.07.017</ext-link></comment> <object-id pub-id-type="pmid">23939492</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anand</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Qi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Artero</surname> <given-names>PC</given-names></name>, <etal>et al</etal>. <article-title>BET bromodomains mediate transcriptional pause release in heart failure</article-title>. <source>Cell</source>. <year>2013</year> <month>Aug</month> <day>1</day>;<volume>154</volume>(<issue>3</issue>):<fpage>569</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2013.07.013" xlink:type="simple">10.1016/j.cell.2013.07.013</ext-link></comment> <object-id pub-id-type="pmid">23911322</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boehm</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Conrad</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Ott</surname> <given-names>M</given-names></name>. <article-title>Bromodomain proteins in HIV infection</article-title>. <source>Viruses</source>. <year>2013</year> <month>Jun</month>;<volume>5</volume>(<issue>6</issue>):<fpage>1571</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/v5061571" xlink:type="simple">10.3390/v5061571</ext-link></comment> <object-id pub-id-type="pmid">23793227</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mertz</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Conery</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Bryant</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Sandy</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Balasubramanian</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mele</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. <article-title>Targeting MYC dependence in cancer by inhibiting BET bromodomains</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2011</year> <month>Oct</month> <day>4</day>;<volume>108</volume>(<issue>40</issue>):<fpage>16669</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1108190108" xlink:type="simple">10.1073/pnas.1108190108</ext-link></comment> <object-id pub-id-type="pmid">21949397</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Edwards</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Arrowsmith</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Bountra</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bunnage</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Feldmann</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Knight</surname> <given-names>JC</given-names></name>, <etal>et al</etal>. <article-title>Preclinical target validation using patient-derived cells</article-title>. <source>Nat Rev Drug Discov</source>. <year>2015</year> <month>Mar</month>;<volume>14</volume>(<issue>3</issue>):<fpage>149</fpage>–<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd4565" xlink:type="simple">10.1038/nrd4565</ext-link></comment> <object-id pub-id-type="pmid">25722227</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mohedas</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>Xing</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Armstrong</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Bullock</surname> <given-names>AN</given-names></name>, <name name-style="western"><surname>Cuny</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>PB</given-names></name>. <article-title>Development of an ALK2-biased BMP type I receptor kinase inhibitor</article-title>. <source>ACS Chem Biol</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>1291</fpage>–<lpage>302</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/cb300655w" xlink:type="simple">10.1021/cb300655w</ext-link></comment> <object-id pub-id-type="pmid">23547776</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sanvitale</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Kerr</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Chaikuad</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ramel</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Mohedas</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>Reichert</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>A new class of small molecule inhibitor of BMP signaling</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e62721</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0062721" xlink:type="simple">10.1371/journal.pone.0062721</ext-link></comment> <object-id pub-id-type="pmid">23646137</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chaikuad</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Alfano</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kerr</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Sanvitale</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Boergermann</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Triffitt</surname> <given-names>JT</given-names></name>, <etal>et al</etal>. <article-title>Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva</article-title>. <source>J Biol Chem</source>. <year>2012</year> <month>Oct</month> <day>26</day>;<volume>287</volume>(<issue>44</issue>):<fpage>36990</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M112.365932" xlink:type="simple">10.1074/jbc.M112.365932</ext-link></comment> <object-id pub-id-type="pmid">22977237</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dolgin</surname> <given-names>E</given-names></name>. <article-title>Patent-free pact pushes the boundaries of precompetitive research</article-title>. <source>Nat Med</source>. <year>2014</year> <month>Jun</month>;<volume>20</volume>(<issue>6</issue>):<fpage>564</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm0614-564" xlink:type="simple">10.1038/nm0614-564</ext-link></comment> <object-id pub-id-type="pmid">24901552</object-id></mixed-citation></ref>
<ref id="pbio.1002164.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Edwards</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Isserlin</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bader</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Frye</surname> <given-names>SV</given-names></name>, <name name-style="western"><surname>Willson</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>FH</given-names></name>. <article-title>Too many roads not taken</article-title>. <source>Nature</source>. <year>2011</year> <month>Feb</month> <day>10</day>;<volume>470</volume>(<issue>7333</issue>):<fpage>163</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/470163a" xlink:type="simple">10.1038/470163a</ext-link></comment> <object-id pub-id-type="pmid">21307913</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>